EuroMedtech™ 2012 Program

M&A activity picked up speed in 2010 but dealmaking is looking very different after the downturn. Examining deals from last year, this panel will look at the ins and outs of making a deal in the post recession market. How are new pressures, such as a buyer preference for profit-making companies, affecting M&A and how can a young company position itself in a buyer's market? What new strategies are being used to decrease deal risk? And are there new players on the field that young companies and their investors can turn to for exit possibilities? Perspectives from both sides of the table will illustrate the hurdles facing M&A and collaborative transactions in a new healthcare ecosystem.

Moderator:
Olivier Litzka – Partner, Edmond de Rothschild Investment

Panelists:

• Simon Cartmell – Executive Chairman, OSspray
• Laurent Grandidier – VP Sales and Marketing, Endosense
• Nigel Pitchford – Partner, DFJ Esprit
• Crispin Simon – formerly CEO, BioCompatibles and Executive Chairman, Occam Medical Ventures

2010 was a year of changes and challenges in the medtech area, all of which will affect the ways companies do business in 2011 and beyond. Faced with a struggling global economy, an uncertain regulatory environment in the largest medtech market, and a decrease in investor funds, how can the medtech industry retain innovation levels and continued growth? Starting with a half year update on Ernst & Young's annual Pulse of the Industry report, Heinrich Christen will lead this expert panel in a discussion of the different pressures creating a "health outcomes ecosystem" and how this new business model will change medtech companies in the future. Where are the possibilities for growth? What strategies must traditional companies adopt to succeed in this new environment? And how will a more collaborative approach to doing business benefit companies, investors and, ultimately, patients?

Moderator:
Heinrich Christen – Partner and Industry Leader, Medical Devices EMEIA, Ernst & Young

Panelists:

• Markus Christen – Head of Business Development, Patient Franchises, Molecular Diagnostics Liaison, Novartis Pharma
• Jason Hillenbach – Associate Director, Global Life Sciences Center, Ernst & Young
• Tim Lenihan – CEO, MD Start
• Josep Ll. Sanfeliu – Partner, Ysios Capital Partners

One of the most exciting growth areas within the medtech industry is undoubtedly telehealthcare technologies. Encompassing remote monitoring, services that allow for greater flexibility in physician/patient interaction, and wellness technologies, telehealthcare combines medtech expertise with ICT tools. Expectations are high, with many analysts viewing it as the way health systems can deal with some of the pressures to be more efficient and cost-effective. But hurdles still remain before the telehealthcare explosion can be realized, not the least of which is the lack of a business model(s). This panel will explore some of the options being used today and discuss how the traditional business model could change to increase interplay among elective, statutory and insurance based systems to exploit the potential of this developing sector.

Moderator:
Sue Dunkerton – Co-Director, HealthTech & Medicines KTN

Panelists:

• Emmanuele Angione – Head of Operations, WIN
• Tony Davis – CEO, MedilinkWM and Chair, MedilinkUK
• Bill McKeon – CEO, Cellnovo

With an aging population comes chronic conditions, not the least of which is pain. Pain management was the original application of neuromodulation, allowing the current demographic shift to propel a number of developments in this area. In addition to more effective and less invasive devices, new therapeutic applications of neuromodulation have also been explored and developed in conditions from obesity to Parkinson's disease. This panel will examine the newest developments in neuromodulation therapy, including deep brain stimulation and sacral nerve stimulation, the materials, technologies and collaborations that are needed for these new developments to succeed, as well as what therapies will drive future growth.

Moderator:
Kamran Rafiq – Managing Director, GlobalData

Panelists:

• Sjaak Deckers – CEO, Sapiens
• Ulf Pommerening – CEO, EBS Technologies
• Dr Karl Schweitzer – VP and International General Manager, Medtronic Neuromodulation

A favorable regulatory environment. A head start on the BRIC countries. Ample resources for innovation. A wobbling but still standing investment community. All of these factors combine to create a unique window of opportunity for the European healthcare industry. With a difficult regulatory environment in the USA leading to a longer and more expensive route to market than many young companies can afford, Europe is quickly becoming the first location to launch products, run clinical trials and often turn to for investment. How can medtech companies, both European and international, capitalize on this situation? The model of US companies setting up shop in Europe, with VCs who can take advantage of available soft funding for portfolio companies and use ample clinical data from European studies for later US approval is gaining traction. Will American VCs follow this wave and be more willing to invest or co-invest with their European counterparts, flipping the old model upside down?

How can Europe maintain its unique position as a leading innovative environment in the face of rising competition from China, Brazil and India, whose huge resources (and markets) are only starting to impact their healthcare systems? The opportunity is there for the taking: What do European regulators, companies, investors and healthcare providers need to do to take advantage of it?

Moderator:
Robert Keefer – Partner, TCG

Panelists:

• Ruediger Herrmann – Partner, WilmerHale
• Marion Jung – Principal, Earlybird Venture Capital
• Bill Starling – CEO, Synecor
• Klaus Stoeckemann – Managing Partner, Charité Biomedical Fund, c/o Peppermint Venture Partners

The cluster model is an oft touted mechanism of innovation and SME support, but what is the reality of growing a company with such a mechanism? Can the geographical proximity of small and large companies, investors or fund providers, research facilities and personnel really play an instrumental role in helping a company grow, especially in an increasingly digitally connected world? This panel will provide case studies of companies whose cluster involvement was crucial to their growth and success and explore why clusters can play an important role in the development of companies of all sizes in spite of, or perhaps because of, increasing global interconnection.

Moderator:
Fabrizio Conicella – General Manager, Bioindustry Park Silvano Fumero and BioPmed Cluster

Panelists:

• Yanis Caritu – Co-Founder and Software Fellow, Movea
• Piero Costa – Head of Research and Development, Traumavet
• Michael Vardi – CEO and Co-Founder, EStimME

Surgically innovative procedures are increasingly incorporating a variety of tools from other medtech sectors not traditionally seen in the operating room. With the use of NOTES and other minimally invasive techniques, imaging capabilities, ICT technologies and robotics have become integral parts of procedures and have also resulted in systems that are transforming the way surgeons are trained and their preparation for surgeries. This panel will discuss the major advances made possible by innovation in surgical tools and procedures, how these advances provide opportunities for medtech companies and what the increasing integration of different systems means for how companies will do business in the future.

Moderator:
André-Michel Ballester – CEO, Sorin Group

Panelists:

• Paula Gomes – Global Medical Technology Practice, Cambridge Consultants
• Andrea Venturelli – VP Research and Development, CTO Business Unit, Medtronic Peripheral

As medical device innovation reaches further into the IT field to deliver the tools and processes needed to provide quality healthcare at lower costs, a major hurdle to overcome is interoperability between those same tools and processes. Touching everything from electronic medical records (EMR) to imaging systems to home monitoring devices, the need for healthcare tools to seamlessly communicate has become increasingly important for hospitals, physicians and patients. More importantly, the interoperability hurdle can determine the access companies have to their target market, with a lack of interoperabiltiy resulting in smaller companies being squeezed out and a decrease, not just in system choice, but also in overall access to innovation.

This panel will explore the specific characteristics of the medtech industry that make this issue paramount for future innovation, the key players needed to make interoperability a success, the effect of adopting interoperability standards on how medical technology companies do business, and the way interoperability will allow the next generation of medical technologies to meet the challenges of the changing healthcare landscape.

Moderator:
Prof Dr Erwin Keeve – Director Clinical Navigation, Charité Universitaetsmedizin Berlin

Panelists:

• Joe Cafazzo – Lead, Centre for Global eHealth Innovation, University Health Network, University of Toronto
• Marco Mattiuzzi – Technology Integration Manager, Bracco Imaging
• Juan Soto – Senior Research Scientist, Fraunhofer Institute FOKUS